Anthony has led launches in cardiovascular, oncology, ophthalmology, and rare disease, built and scaled national field teams, and advanced innovative market access and patient engagement models.
Anthony currently leads the build-out of commercial infrastructure for the rare disease division at REGENXBIO, bringing a disciplined, execution-focused perspective, investor-minded perspective grounded in operational rigor, disciplined capital deployment, and long-term franchise building.